PYY and pancreatic neoplasm: Moreover, PYY and its fragments (e.g., PYY14-36) decreased the development of pancreatic tumor cells [206,207,209], and BIM-43004-1, a modified PYY22-36 Y2R synthetic agonist, also reduced the growth of these cells [207,208].